

DAFTAR PUSTAKA

- Aapro, M., 2013. Biosimilars in oncology: current and future perspectives. *Generics and Biosimilars Initiative Journal*, **2**: 91–93.
- Aapro, M., Crawford, J., dan Kamioner, D., 2010. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer*, **18**: 529–541.
- Aapro, M.S., Bohlius, J., Cameron, D.A., Lago, L.D., Donnelly, J.P., Kearney, N., dkk., 2011. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. *European Journal of Cancer*, **47**: 8–32.
- Aapro, M.S., Cameron, D.A., Pettengell, R., Bohlius, J., Crawford, J., Ellis, M., dkk., European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party, 2006. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. *European Journal of Cancer (Oxford, England: 1990)*, **42**: 2433–2453.
- Abeloff, M.D., Armitage, J.O., Niederhuber, J.E., Kastan, M.B., dan McKenna, W.G., 2008. *Abeloff's Clinical Oncology: Expert Consult - Online and Print, 4e*, 4 edition. ed. Churchill Livingstone, Philadelphia.
- Advani, S.H., Achrekar, S., Thomas, D., dan Krishnankutty, B., 2010. Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia. *Indian Journal of Medical and Paediatric Oncology: Official Journal of Indian Society of Medical & Paediatric Oncology*, **31**: 79–82.
- Airley, R., 2009. *Cancer Chemotherapy Basic Science to the Clinic*, First. ed. Wiley-Blackwell.
- Alberta Health Services, 2014. Management of febrile neutropenia in adult cancer patient. *Clinical Practice Guideline, Version 3*: 1–19.
- Alexandre, J., Gross-Goupil, M., Falissard, B., Nguyen, M.-L., Gornet, J.-M., Misset, J.-L., dkk., 2003. Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. *Annals of Oncology*, **14**: 36–41.
- Anderson, P.O., Knoben, J.E., dan Troutman, W.G., 2002. *Handbook of Clinical Drug Data*. McGraw-Hill Medical Pub. Division.

- Anonim, 2002. *AHFS Drug Information*. American Society of Health-System Pharmacists, Bethesda, USA.
- Anonim, 2010. Neutropenia in cancer patients: Risk Factors and Management. *European School of Oncology e-grandround*, 15–22.
- Ansel, H. dan Prince, S., 2006. *Kalkulasi Farmasetik: Panduan Untuk Apoteker*. EGC, Jakarta.
- Aspinall, R., 2005. Ageing and the immune system in vivo: commentary on the 16th session of British Society for Immunology Annual Congress, Harrogate, December 2004. *Immunity & ageing : I & A*, **2**: 5.
- Astuti, L., 2004. 'Evaluasi Penggunaan Granulocyte Colony Stimulating Factor Pada Pasien Kanker Limfoma Setelah Mendapat Kemoterapi di RS. Kanker Dharmais Jakarta, Periode Januari 2001- September 2003', . Fakultas Farmasi UGM, Yogyakarta Indonesia.
- Balducci, L., Hardy, C.L., dan Lyman, G.H., 2000. Hemopoietic reserve in the older cancer patient: clinical and economic considerations. *Cancer Control: Journal of the Moffitt Cancer Center*, **7**: 539–547.
- Barni, S., Lorusso, V., Giordano, M., Sogno, G., Gamucci, T., Santoro, A., dkk., 2014. A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. *Springer. Med Oncol (2014)*, **31:797**: 1–7.
- Bhatt, V. dan Saleem, A., 2004. R eview: Drug-Induced Neutropenia – Pathophysiology, Clinical Features, and Management. *Annals of Clinical and Laboratory Science*, **34 No 2**: 131–137.
- Bolis, S., Cocorocchio, E., Corti, C., Ferreri, A.J.M., Frungillo, N., Grillo, G., dkk., 2013. Clinical implications, safety, efficacy of recombinant human Granulocyte Colony-Stimulating Factors and pegylated equivalent. *Epidemiology Biostatistics and Public Health*, **10 Number 4**: 1–16.
- Carr, J., 2012. Guideline for the Use of Granulocyte-Colony Stimulating Factor (G-CSF) in Adult Patients. *NHS*, 1–10.
- Chan, A., Chen, C., Chiang, J., Tan, S.H., dan Ng, R., 2012. Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer*, **20**: 1525–1532.

- Chan, A., Lee, C.P., Chiang, J., dan Ng, R., 2013. Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas. *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer*, **21**: 2137–2143.
- Collett, D., 2015. *Modelling Survival Data in Medical Research, Third Edition*. CRC Press.
- Cooper, K.L., Madan, J., Whyte, S., Stevenson, M.D., dan Akehurst, R.L., 2011. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. *BMC Cancer*, **11**: 404.
- Corwin, E.J., 2009. *Buku Saku Patofisiologi*, 3rd ed. EGC, Jakarta.
- Crawford, J., Armitage, J., Balducci, L., Becker, P.S., Blayney, D.W., Cataland, S.R., dkk., 2013. Myeloid Growth Factors. *Journal of the National Comprehensive Cancer Network*, **11**: 1266–1290.
- Crawford, J., Caserta, C., dan Roila, F., 2010. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. *Annals of Oncology*, **21**: v248–v251.
- Crawford, J., Dale, D.C., Kuderer, N.M., Culakova, E., Poniewierski, M.S., Wolff, D., dkk., 2008. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. *Journal of the National Comprehensive Cancer Network: JNCCN*, **6**: 109–118.
- Crawford, J., Dale, D.C., dan Lyman, G.H., 2003. Chemotherapy-Induced Neutropenia Risks, Consequences, and New Directions for Its Management. *American Cancer Society*, **100**: 228–237.
- Crawford, J., Glaspy, J.A., Stoller, R.G., Tomita, D.K., Vincent, M.E., McGuire, B.W., dkk., 2005. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. *Supportive Cancer Therapy*, **3**: 36–46.
- Dahlan, S., 2013. *Besar Sampel Dan Cara Pengambilan Sampel Dalam Penelitian Kefokteran Dan Kesehatan*, 3rd ed, Evidence Based Medicine 2. Salemba Medika, Jakarta.
- Davey, P., 2005. *At a Glance Medicine*. Erlangga, Jakarta.

- Del Giglio, A., Eniu, A., Ganea-Motan, D., Topuzov, E., dan Lubenau, H., 2008. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. *BMC cancer*, **8**: 332.
- Demetri, G.D. dan Griffin, J.D., 1991. Granulocyte colony-stimulating factor and its receptor. *Blood*, **78**: 2791–2808.
- Dipiro, J., Malone, P., Kolesar, J., Rotschafer, J., Chisholm-Burns, M., dan Wells, B.G., 2007. *Pharmacotherapy Principles & Practice*. McGraw Hill Professional.
- Doshi, B.D., Pandya, N.M., Shah, C.A., Gupta, A.K., dan Makwana, M.V., 2012. Chemotherapy-induced Neutropenia in cancer patients with solid tumors in India. *Scholars Research Library, Der Pharmacia Lettre*, **4(2)**: 584–590.
- Drew, R.H., 2013. Prevention And Treatment Of Infections In Neutropenic Cancer Patient, dalam: Alldredge, B.K., Corelli, R.L., Ersnt, M.E., Guglielmo, B.J., Jacobson, P.A., Kradjan, W.A., dkk. (Editor), *Koda Kimble And Youngs Applied Therapeutics The Clinical Use Of Drugs*. Wolters Kluwers Health Lippincots Williams&Wilkins, Philadelphia USA, hal. 1672–1674.
- Efferth, T. dan Volm, M., 2005. Pharmacogenetics for individualized cancer chemotherapy. *Pharmacology & Therapeutics*, **107**: 155–176.
- European Medicines Agency, 2010. CHMP assessment report Nivestim International Non-proprietary Name: filgrastim. *Committee for Medicinal Products for Human Use*, 36.
- Fausto, N., Kumar, V., Abbas, A.K., dan Mitchcell, R.N., 2008. *Dasar Patologis Penyakit*. EGC, Jakarta.
- Gascon, P., 2012. Presently available biosimilars in hematology-oncology: G-CSF. *Targeted Oncology*, **7 Suppl 1**: S29–34.
- Gatzemeier, U., Ciuleanu, T., Dediu, M., Ganea-Motan, E., Lubenau, H., dan Del Giglio, A., 2009. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*, **4**: 736–740.

- Green, M.D., Koelbl, H., Baselga, J., Galid, A., Guillem, V., Gascon, P., dkk., International Pegfilgrastim 749 Study Group, 2003. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. *Annals of oncology: official journal of the European Society for Medical Oncology / ESMO*, **14**: 29–35.
- Guo, S., 2009. *Survival Analysis*. Oxford University Press, USA.
- Haustein, R., 2012. Saving money in the European healthcare systems with biosimilars. *Generics and Biosimilars Initiative Journal*, **1**: 120–126.
- Hoffbrand, A.V., Pettit, J.E., dan Moss, P.A., 2005. *Kapita Selektta Hematologi*, 4th ed. Buku Kedokteran EGC, Jakarta.
- Hoffman, J., Thomas, E., dan Dombrowski, S., 2013. A Health-System Pharmacist's Guide to Bisimilars: Regulatory, Scientific, and Practical Considerations. *American Society of Health-System Pharmacist's*, 1–12.
- Holmes, F.A., Jones, S.E., O'Shaughnessy, J., Vukelja, S., George, T., Savin, M., dkk., 2002a. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. *Annals of oncology: official journal of the European Society for Medical Oncology / ESMO*, **13**: 903–909.
- Holmes, F.A., O'Shaughnessy, J.A., Vukelja, S., Jones, S.E., Shogan, J., Savin, M., dkk., 2002b. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **20**: 727–731.
- Hosmer, W., Malin, J., dan Wong, M., 2011. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer*, **19**: 333–341.
- Hurria, A., Brogan, K., Panageas, K.S., Jakubowski, A., Zauderer, M., Pearce, C., dkk., 2005. Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy. *Drugs & Aging*, **22**: 709–715.
- IARC, 2012. 'GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012', .

- Jilma, B., Jagiełło-Gruszczyńska, A., Tomczak, P., Gadgil, H., Orlik, G., Desai, K., dkk., 2014. Demonstration of Clinical Comparability of the Biosimilar Filgrastim to Neupogen, in Terms of Safety and Efficacy, in Healthy Volunteers and Patients Receiving Myelosuppressive Chemotherapy. *Demonstration of Clinical Comparability of the Biosimilar Filgrastim to Neupogen European Oncology and Haematology*, 107–115.
- Kaku, T., Ogawa, S., Kawano, Y., Ohishi, Y., Kobayashi, H., Hirakawa, T., dkk., 2003. Histological classification of ovarian cancer. *Medical Electron Microscopy*, **36**: 9–17.
- Keefe, D.M. (Editor), 2013. *Pathobiology of Cancer Regimen-Related Toxicities*. Springer Science & Business Media.
- Kemenkes, 2013. 'Riset Kesehatan Dasar', . Kementerian Kesehatan RI, Indonesia.
- Kim, W.Y., Woo, S.U., Seo, J.H., Son, G.S., Lee, J.B., dan Bae, J.W., 2011. Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases. *Journal of Cancer Research and Therapeutics*, **7**: 412–415.
- Kumar, V., Abbas, A.K., Fausto, N., dan Mitchell, R.N. (Editor), 2007. *Robbins Basic Pathology, Eighth Edition*, 8th edition. ed. Saunders/Elsevier, Philadelphia, PA.
- Lacy, C.F., Armstrong, L.L., Goldman, M.P., Lance, L.L., dan Corbett, A.H., 2014. *Drug Information Handbook A Clinically Relevant Resource for All Healthcare Professionals*, 23rd ed. Lexicomp, American Pharmacists Association, Wolters Kluwer, North American.
- Lalami, Y., Paesmans, M., Muanza, F., Barette, M., Plehiers, B., Dubreucq, L., dkk., 2006. Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. *Annals of Oncology*, **17**: 507–514.
- Laskey, R.A., Poniewierski, M.S., Lopez, M.A., Hanna, R.K., Secord, A.A., Gehrig, P.A., dkk., 2012. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. *Gynecologic Oncology*, **125**: 625–630.
- Lemeshow, S., Hosmer Jr., D.W., Klar, J., dan Lwanga, S.K., 1997. *Besar Sampel Dalam Penelitian Kesehatan*. Gadjah Mada University Press, Yogyakarta, Indonesia.
- Lemke, T.L. dan Williams, D.A., 2008. *Foye's Principles of Medicinal Chemistry*. Lippincott Williams & Wilkins.

- Lyman, G.H., Abella, E., dan Pettengell, R., 2014. Risk Factors For Febrile Neutropenia Among Patients With Cancer Receiving Chemotherapy : A Systematic review. *Oncology Hematology*, **90**: 190–199.
- Lyman, G.H. dan Kuderer, N.M., 2003. Epidemiology of febrile neutropenia. *Supportive Cancer Therapy*, **1**: 23–35.
- Lyman, G.H., Kuderer, N.M., Crawford, J., Wolff, D.A., Culakova, E., Poniewierski, M.S., dkk., 2011. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. *Cancer*, **117**: 1917–1927.
- Lyman, G.H. dan Rolston, K.V.I., 2010. How We Treat Febrile Neutropenia in Patients Receiving Cancer Chemotherapy. *Journal of Oncology Practice*, **6**: 149–152.
- Maltzman, J.D. dan Millar, L.B., 2010. 'Chemotherapy Primer: Why? What? and How? | Oncolink - Cancer Resources', . URL: <http://www.oncolink.org/treatment/article.cfm?c=142&id=224> (diakses tanggal 14/10/2014).
- Marrs, J.A., 2006. Care of Patients With Neutropenia. *Clinical Journal of Oncology Nursing*, **10, Number 2**: 164–166.
- Marsh, S., 2005. Thymidylate synthase pharmacogenetics. *Investigational New Drugs*, **23**: 533–537.
- Martins, A., Han, J., dan Kim, S.O., 2010. The Multifaceted Effects of Granulocyte Colony-Stimulating Factor in Immunomodulation and Potential Roles in Intestinal Immune Homeostasis. *IUBMB life*, **62**: 611–617.
- MASCC, 2011. Abstracts of the 2011 International MASCC/ISOO Symposium Supportive Care In Cancer. *Springer, Support Care Cancer (2011)*, **19 (Suppl 2)**: S68–S370.
- McPherson, R.A. dan Sacher, R.A., 2004. *Tinjauan Klinis Hasil Pemeriksaan, Laboratorium*, 11th ed. EGC, Jakarta.
- Menteri Kesehatan Republik Indonesia, 2013. Keputusan Menteri Kesehatan Republik Indonesia Nomor 328/MENKES/SK/VIII/2013 Tentang Formularium Nasional.
- Meza, L.A., Green, M.D., Hackett, J.R., Neumann, T.A., dan Holmes, F.A., 2003. Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin. *Pharmacotherapy*, **23**: 1424–1431.

- Michael, M. dan Doherty, M.M., 2005. Tumoral drug metabolism: overview and its implications for cancer therapy. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **23**: 205–229.
- Murti, I.S., 2005. 'Pemberian Granulocyte Colony Stimulating Factor (GCSF) Sebagai Tindakan Preventif Primer Neutropeni Derajat 3-4 Pada Penderita Kanker Payudara Usia Lanjut Yang Memperoleh Kemoterapi Ajuvant Fluorourasil, Epirubicin Dan Cyclophosphamid (FEC 100)', . Fakultas Kedokteran UGM, Yogyakarta Indonesia.
- NCCN Guidelines, 2013. Prevention and Treatment of Cancer-Related Infection. *Clinical Practice Guidelines in Oncology*, **Version 1**.
- NCCN Guidelines, 2014a. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. *Clinical Practice Guidelines in Oncology*, **Version 3**.
- NCCN Guidelines, 2014b. Myeloid Growth Factors. *Clinical Practice Guidelines in Oncology*, **Version 2**.
- NCI, 2006. Common Terminology Criteria for Adverse Events (CTCAE). *DCTD, NCI, NIH, DHHS*, **Version 3**: 3.
- NCI, 2009. Common Terminology Criteria for Adverse Events (CTCAE). *U.S. Department Of Health And Human Services, National Institutes Of Health, National Cancer Institue*, **Version 4**: 3–4.
- Okishiro, M., Kim, S.J., Tsunashima, R., Nakayama, T., Shimazu, K., Shimomura, A., dkk., 2011. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide. *Breast Cancer Research and Treatment*, **132**: 947–953.
- Orciuolo, E., Buda, G., Marturano, E., Mauro, E., Milone, G., Cangialosi, C., dkk., 2011. Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. *Leukemia Research*, **35**: 899–903.
- Otto, S.E., 2003. *Buku Saku Keperawatan Onkologi*, 1st ed. EGC, Jakarta.
- Ozawa, K., Minami, H., dan Sato, H., 2007. Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients. *Cancer Chemotherapy and Pharmacology*, **62**: 551–557.

- Park, K.H., Sohn, J.H., Lee, S., Park, J.H., Kang, S.Y., Kim, H.Y., dkk., 2013. A randomize, mlti-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated GCSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. *Invest New Drug*, **31**: 1300–1306.
- Perry, M.C., 2008. *The Chemotherapy Source Book*, 4th ed. Lippincott Williams & Wilkins, USA.
- Peter, J., Sean, E., dan Sylvie, F., 2007. 'Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer.', *Science.NaturalNews.com*. URL: http://science.naturalnews.com/4462239_Obesity_is_not_associated_with_increased_myelosuppression_in_patients_receiving.html (diakses tanggal 25/5/2015).
- Peterson, G.M., 2011. Generic substitution: a need for clarification. *British Journal of Clinical Pharmacology*, **71**: 966–967.
- Petros, W.P., Hopkins, P.J., Spruill, S., Broadwater, G., Vredenburg, J.J., Colvin, O.M., dkk., 2005. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **23**: 6117–6125.
- Pettengell, R., Bosly, A., Szucs, T.D., Jackisch, C., Leonard, R., Paridaens, R., dkk., 2008. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. *British Journal of Haematology*, **144**: 677–685.
- Root, R.K. dan Dale, D.C., 1999. Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor: Comparisons and Potential for Use in the Treatment of Infections in Nonneutropenic Patients. *Journal of Infectious Diseases*, **179**: S342–S352.
- Sagara, Y., Sato, K., Fukuma, E., Higaki, K., Mizutani, M., Osaki, A., dkk., 2013. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer. *Japanese Journal of Clinical Oncology*, **43**: 865–873.
- Schouten, H.C., 2006. Neutropenia management. *Annals of Oncology*, 85–89.

- Schwenkglenks, M., Jackisch, C., Constenla, M., Kerger, J.N., Paridaens, R., Auerbach, L., dkk., 2006. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer*, **14**: 901–909.
- Seung, A.H., 2013. Adverse Effects of Chemotherapy and Targeted Agents, dalam: Alldredge, B.K., Corelli, R.L., Ersnt, M.E., Guglielmo, B.J., Jacobson, P.A., dan Kradjan, W.A. (Editor), *Koda Kimble And Youngs Applied Therapeutics The Clinical Use Of Drugs*. Wolters Kluwers Health Lippincots Williams&Wilkins, Philadelphia USA, hal. 2112.
- Singh, V.K., Newman, V.L., dan Seed, T.M., 2015. Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): A review. *Cytokine*, **71**: 22–37.
- Sridhar, T.I., Risk Factors For and Consequences of Febrile Neutropenia in Cancer Chemotherapy Patients by Femida Gwadry, 1996. 'The Incidence, Risk Factors For and Consequences of Febrile Neutropenia in Cancer Chemotherapy Patients', . The University of Western Ontario, London, Ontario.
- Sveikata, A., Gumbrevičius, G., Seštakauskas, K., Kregždýtė, R., Janulionis, V., dan Fokas, V., 2014. Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers. *Medicina (Kaunas, Lithuania)*, **50**: 144–149.
- Tjay, T.H. dan Rahardja, K., 2007. *Obat-Obat Penting : Khasiat, Penggunaan Dan Efek-Efek Sampingnya*, Edisi Keenam. ed. PT. Elex Media Komputindo, Jakarta.
- Travis, W.D., Brambilla, E., Müller-Hermelink, H.K., dan Harris, C.C. (Editor), 2004. *Pathology and Genetics Tumours of the Lung, Pleura, Thymus and Heart*, World Health Organization Classification of Tumours. ed. IARC Press, Lyon.
- Welte, K., Gabilove, J., Bronchud, M.H., Platzer, E., dan Morstyn, G., 1996. Filgrastim (r-metHuG-CSF): the first 10 years. *Blood*, **88**: 1907–1929.
- Weycker, D., Li, X., Edelsberg, J., Barron, R., Kartashov, A., Xu, H., dkk., 2014. Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens. *Springer-Verlag Berlin Heidelberg, Support Care Cancer*, 1–11.